Skip to main content

Table 2 Demographic and clinicopathological parameters of PAAD patients based on TCGA datasets

From: Quantification of m6A RNA methylation modulators pattern was a potential biomarker for prognosis and associated with tumor immune microenvironment of pancreatic adenocarcinoma

Clinical characteristics All High m6Ascore low m6Ascore P value
Age 64.54 ± 10.81 63.74 ± 11.68 65.33 ± 9.88 0.387
Gender     0.735
 Female 66 34 32  
 Male 74 36 38  
Race     0.689
 Asian 8 5 3  
 White 123 60 63  
 Black or African American 5 2 3  
Fustat     < 0.001
 Living 63 21 42  
 Deceased 77 49 28  
Pathologic stage     0.927
 I (IA + IB) 12 6 6  
 II (IIA + IIB) 121 60 61  
 III+ IV 7 4 3  
T     0.813
 T1+ T2 21 10 11  
 T3 + T4 119 60 59  
M     0.361
 M0 66 34 32  
 M1 4 3 1  
N     0.808
 N0 37 19 18  
 N1(N1a + N1b) 102 50 52  
Histologic grade     0.140
 G1-G2 98 45 53  
 G3-G4 42 25 17  
Site
 Head of pancreas 110 54 56 0.139
 Body of pancreas 11 8 3  
 Tail of pancreas 10 6 4  
 others 9 2 7  
 Maximum tumor dimension 3.75 ± 1.44 4.05 ± 1.72 3.42 ± 0.98 0.013
History of targeted molecular therapy     0.185
 YES 75 37 38  
 NO 35 22 13  
Alcohol drinking history     0.910
 YES 80 40 40  
 NO 49 24 25  
History of chronic pancreatitis     0.726
 YES 12 7 5  
 NO 100 53 47  
History of diabetes     0.157
 YES 32 13 19  
 NO 85 47 38  
Family history of cancer     0.910
 YES 50 21 29  
 NO 33 23 10  
  1. Annotation: Numbers that do not add up to 100% are attributable to missing data